RxDoctor Payments Data

Piero Simone, MD

Ophthalmology · Warren, MINPI 1497769624

Payments from drug & device makers

$909in general payments, 2019–2025

Across 35 payments — averaging $25.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$152
  • Sun Pharmaceutical Industries Inc.$141
  • Carl Zeiss Meditec USA, Inc.$112
  • Omeros Corporation$72
  • Ocular Therapeutix, Inc.$62
  • Rayner Intraocular Lenses Limited$50
  • plus $320 from 11 others

What the payments were for

  • Food & beverage$909100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$909 in reported general payments places this provider in the 45th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$421,069
Medicare patients
1,320
Services billed
3,095

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine116$138,981
Cyclosporine82$45,995
LumiganBimatoprost70$29,253
Loteprednol Etabonate90$19,240
Tobramycin-DexamethasoneTobramycin/Dexamethasone298$13,841
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol58$10,356
Latanoprost488$8,054
Brimonidine Tartrate84$7,399
Timolol Maleate140$6,894
Fluorometholone73$5,919
CombiganBrimonidine Tartrate/Timolol31$5,755
Prednisolone Acetate139$4,970
Azelastine Hcl215$4,527
Bimatoprost32$3,596
FlarexFluorometholone Acetate17$3,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$36$173,989217 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$20$19,24090 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Warren

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →